US patent granted for Therakind’s DriDose® multi-dose delivery system
Patent further strengthens Therakind’s extensive patent portfolio protecting its proprietary range of dry powder delivery devices
London, England, November 27 – Therakind, a specialty pharmaceutical company focused on developing and delivering niche medicines for difficult-to-treat patient groups, announces that the United States Patent and Trademark Office has granted a patent protecting the Company’s novel multi-dose, needle-free version of its dry powder nasal drug delivery system, DriDose®.
The utility patent protects the mechanism of dry powder delivery using DriDose’s unique delivery system. Therakind also has patents granted in China and Japan and pending in other major territories for the multi-dose version. The unit dose version of the DriDose® device has active patents in major territories including US, Europe, and China.
The DriDose® dry powder nasal delivery device range is designed to incorporate various types of pharmaceutical candidates. The technology includes both single-use and reusable versions, each capable of being modified to accommodate different powder-loading capacities. The reusable device is designed to reduce plastic waste associated with single-use devices and injections. The DriDose® device aims to simplify drug delivery and is designed to accommodate self-administration. The technology has been validated in a clinical trial and tested with a range of molecules in both in vivo and in vitro settings.
Following a successful management buy-out in March 2024, Therakind primarily focuses on developing DriDose® with multiple in-house and partnered projects in the pipeline. Therakind has recently secured Innovate UK grant funding to develop the DriDose® device with an antiemetic candidate. The company offers a proof-of concept programme for pharmaceutical companies interested in nasal drug administration. The programme utilises Therakind’s proprietary technologies and technical know-how to perform a feasibility study to derisk the programme prior to further development.
For those interested in partnering DriDose® with Therakind, contact [email protected]
